DR29 DataRelease
Release Date: 01/16/2019
| SDY570: UT_SSc | |||||||
| Status: | New | ||||||
| Description: | HLA Genotyping | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3IJD4LQR5 | ||||||
| Subjects: | 997 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: |
|
||||||
| Clinical Assessments: | None | ||||||
| SDY857: Prevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan) Therapy in Cardiac Transplantation | |||||||
| Status: | New | ||||||
| Description: | All people who have a heart transplant are at risk for developing cardiac allograft vasculopathy (CAV). CAV means narrowing of the heart transplant vessels, which is associated with poor heart transplant function. People who develop antibodies after transplant have a higher risk of developing CAV. Infections, high cholesterol, and rejection also increase the risk of developing CAV. People who develop CAV usually have to receive another transplant. The purpose of this research study is to see if a study drug called Rituximab prevents CAV. Rituximab destroys certain types of white blood cells called B cells. B cells are important cells in the immune system that help the body fight infection by producing substances called antibodies. B cells and the antibodies they produce are also involved in some kinds of rejection after organ transplantation. Rituximab decreases the number of B cells in the blood and other tissues. The goal of this study is to determine if decreasing B cells with Rituximab can prevent injury to the transplanted heart. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M33887D0YT | ||||||
| Subjects: | 362 | ||||||
| Study PI, contact: |
|
||||||
| Publications: | None | ||||||
| Resources: |
|
||||||
| Assays: | None | ||||||
| Clinical Assessments: |
|
||||||
| SDY903: Human Immune Signature of Zika virus infection | |||||||||
| Status: | New | ||||||||
| Description: | The human Immune Signature of Zika virus infection was studied in a Zika endemic area, Brazil. T cell responses were compared in acute infected patients as well as convalescent patients. | ||||||||
| Program/Contract: |
|
||||||||
| DOI: | 10.21430/M340DHRY4Y | ||||||||
| Subjects: | 29 | ||||||||
| Study PI, contact: |
|
||||||||
| Publications: | None | ||||||||
| Resources: |
|
||||||||
| Assays: |
|
||||||||
| Clinical Assessments: | None | ||||||||
| SDY960: Viral Triggers in Pediatric Lung Transplantation | |||||||
| Status: | New | ||||||
| Description: | This is a non-randomized observational study to determine whether respiratory viral infections increase the risk of bronchiolitis obliterans syndrome, obliterative bronchiolitis, death or retransplantation in pediatric lung transplant recipients. Comprehensive molecular viral detection will be performed on nasopharyngeal swabs and BAL fluid. Recipient biopsy samples, BAL, serum and PBMC will be obtained at the timepoints outlined in Appendix 1 to assess viral infection, innate immune activity, and adaptive cellular and humoral immunity. Donor specimens (lymph nodes, spleen or blood) will be collected at transplant for use in cellular immune assays. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3Z0LCNUGG | ||||||
| Subjects: | 78 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: |
|
||||||
| Clinical Assessments: |
|
||||||
| SDY1092: Transcriptional responses induced by controlled human malaria infection (CHMI) | |||||||
| Status: | New | ||||||
| Description: | Whole blood RNA-Seq was applied to investigate gene expression kinetics in Tanzanian males who underwent controlled malaria infection by intradermal injection with aseptic, purified, cryopreserved Plasmodium falciparum sporozoites. Building on PfSPZ challenge study: ClinicalTrials.gov Identifier: NCT01540903, PUBMED:PMC4155546 | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M32AARFE8U | ||||||
| Subjects: | 10 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: |
|
||||||
| Clinical Assessments: | None | ||||||
| SDY1095: A Retrospective Multicenter Study to Determine 4-Year Clinical Outcomes in Subjects Previously Enrolled in the CTOT-05 Study | |||||||
| Status: | New | ||||||
| Description: | This study is a multicenter, non-randomized, retrospective study to collect long term (4 years post-transplant) clinical outcome data on subjects previously enrolled in the CTOT-05 study. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M34I2CELSW | ||||||
| Subjects: | 180 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: | None | ||||||
| Clinical Assessments: |
|
||||||
| SDY1119: Systems Biology of 2011 trivalent Influenza vaccine (TIV) in young and elderly individuals, healthy or with T2D (see companion study SDY61 2007, SDY270 2009, SDY56 2010) | |||||||
| Status: | New | ||||||
| Description: | Blood samples will be collected at days 0 (pre-vaccination) and 3,7,30,180 after vaccination. Peripheral blood mononuclear cells | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3ZU72TO6V | ||||||
| Subjects: | 78 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: |
|
||||||
| Clinical Assessments: | None | ||||||
| SDY1294: A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine. | |||||||
| Status: | New | ||||||
| Description: | In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity. We conducted a cohort study in which 21 healthy subjects in China were administered one dose of the YF-17D vaccine; PBMCs were collected at 0 h and then at 4 h and days 1, 2, 3, 5, 7, 14, 28, 84, and 168 postvaccination, and analyzed by transcriptional profiling and immunological assays. At 4 h postvaccination, genes associated with innate cell differentiation and cytokine pathways were dramatically downregulated, whereas receptor genes were upregulated, compared with their baseline levels at 0 h. Immune response pathways were primarily upregulated on days 5 and 7, accompanied by the upregulation of the transcriptional factors JUP, STAT1, and EIF2AK2. We also observed robust activation of innate immunity within 2 d postvaccination and a durable adaptive response, as assessed by transcriptional profiling. Coexpression network analysis indicated that lysosome activity and lymphocyte proliferation were associated with dendritic cell (DC) and CD4+ T cell responses; FGL2, NFAM1, CCR1, and TNFSF13B were involved in these associations. Moreover, individuals who were baseline-seropositive for Abs against another flavivirus exhibited significantly impaired DC, NK cell, and T cell function in response to YF-17D vaccination. Overall, our findings indicate that YF-17D vaccination induces a prompt innate immune response and DC activation, a robust Ag-specific T cell response, and a persistent B cell/memory B cell response. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3LT8WVHVH | ||||||
| Subjects: | 21 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: |
|
||||||
| Clinical Assessments: | None | ||||||
| SDY1295: Perceived Barriers to Patient Adherence after Pediatric Solid Organ Transplantation | |||||||
| Status: | New | ||||||
| Description: | This is a two part prospective, observational, multi-center cohort study of SOT recipients. The first part is a cross sectional comparison of perceived barriers to adherence to post-transplant immunosuppressant regimens in parents of children (0-11 years) versus adolescents (12-21 years). The second is a longitudinal study to evaluate whether perceived barriers to adherence increase with time during the first year following transplantation. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3VRZ0ZS5P | ||||||
| Subjects: | 502 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: | None | ||||||
| Clinical Assessments: | None | ||||||
| SDY1371: Profiling of NK cell ligands on moocytes infected with Influenza A virus | |||||||
| Status: | New | ||||||
| Description: | Goal for the study was to identify NK cell ligands regulated by influenza A virus infection. More specifically we asked whether A/California/07/2009 or A/Victoria/361/2011 virus influenza A viruses differentially modulate NK cell ligands. Using 9 healthy Stanford blood bank donors, we isolated monocytes and NK cells. Monocytes were infected for 1 hr, followed by co-culture with NK cells for 6 or 23 hr hours. Brefeldin adn Monenin were added for the last 4 hours. They were then stained with a CyTOF panel and run on a Helios Mass cytometer. Two major ligands we found that contributed to the variance between the two strains were CD54 and CD112. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3KPGT3BYF | ||||||
| Subjects: | 9 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: |
|
||||||
| Clinical Assessments: | None | ||||||
| SDY1387: Mechanisms Underlying Asthma Exacerbations Prevented and Persistent With Immune-Based Therapy | ||||||||||
| Status: | New | |||||||||
| Description: | ICAC-29/MUPPITS-1 is a prospective, longitudinal, nested case-control study designed to identify changes in gene transcription predictive of and associated with asthma exacerbations in children ages 6 to 17 years with difficult-to-control, exacerbation-prone asthma. Participants will be followed prospectively for the onset of a cold and a subsequent asthma exacerbation. An internet-based asthma and cold symptom diary will be accessed by participants using a hand-held device. When the participant reports development of a cold, a clinic visit will be scheduled as soon as possible (within 48 hours of cold symptom onset) to collect blood and nasal samples. A second clinic visit will occur 4-6 days from the onset of cold symptoms to obtain samples after the initial cold, but prior to the use of systemic corticosteroids. Participants will be followed for up to two colds or approximately 6 months after Visit 0, whichever comes first. | |||||||||
| Program/Contract: |
|
|||||||||
| DOI: | 10.21430/M3Q1C6388O | |||||||||
| Subjects: | 227 | |||||||||
| Study PI, contact: |
|
|||||||||
| Publications: | None | |||||||||
| Resources: |
|
|||||||||
| Assays: | None | |||||||||
| Clinical Assessments: | None | |||||||||
| SDY1389: Lymph node reservoirs for long-lived memory T cells | |||||||||
| Status: | New | ||||||||
| Description: | Translating studies on T cell function and modulation from mouse models to humans requires extrapolating in vivo results on mouse T cell responses in lymphoid organs (spleen and lymph nodes) to human peripheral blood T cells. However, our understanding of T cell responses in human lymphoid sites and their relation to peripheral blood remains sparse. Here, we used a unique human tissue resource to study human T cells in different anatomical compartments within individual donors, and identify a subset of memory CD8+T cells in LN which maintain a distinct differentiation and functional profile compared to memory CD8+T cells in blood, spleen, bone marrow (BM), and lungs. Whole transcriptome and high dimensional CyTOF profiling reveals that LN memory CD8+T cells express signatures of quiescence and self-renewal compared to corresponding populations in blood, spleen, BM and lung. LN memory T cells exhibit a distinct transcriptional signature including expression of stem cell-associated transcription factors TCF-1, LEF-1, T-follicular helper cell markers CXCR5, and CXCR4, and reduced expression of effector molecules. LN memory T cells display high homology to a subset of mouse CD8+T cells identified in chronic infection models which responds to checkpoint blockade immunotherapy. Functionally, human LN memory T cells exhibit increased proliferation to T cell receptor (TCR)-mediated stimulation and maintain higher TCR clonal diversity compared to memory T cells from blood and other sites. These findings establish human LN as reservoirs for memory T cells with high capacities for expansion and diverse recognition and important targets for immunotherapies. | ||||||||
| Program/Contract: |
|
||||||||
| DOI: | 10.21430/M3NBGEA98C | ||||||||
| Subjects: | 51 | ||||||||
| Study PI, contact: |
|
||||||||
| Publications: |
|
||||||||
| Resources: |
|
||||||||
| Assays: |
|
||||||||
| Clinical Assessments: | None | ||||||||
| SDY1390: CRISPR-Cas9 Engineering in Primary Cell Protocol | |||||||
| Status: | New | ||||||
| Description: | A detailed, peer-reviewed protocol published in Nature Protocols for optimizing CRISPR-Cas9 editing pipelines to primary cell types. A detailed example is provided for editing primary CD4+ T cells to identify HIV host factors. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3R9N6OS6C | ||||||
| Subjects: | 0 | ||||||
| Study PI, contact: |
|
||||||
| Publications: | None | ||||||
| Resources: |
|
||||||
| Assays: | None | ||||||
| Clinical Assessments: | None | ||||||
| SDY1401: Lack of detection of a human placenta microbiome in samples from preterm and term deliveries | |||||||
| Status: | New | ||||||
| Description: | Historically the human womb has been thought to be sterile in healthy pregnancies, but this idea has been challenged by recent studies using DNA sequence-based methods, which have suggested that the womb is colonized with bacteria. For example, analysis of DNA from placenta samples yielded small proportions of microbial sequences, which were proposed to represent normal bacterial colonization. However, an analysis by our group showed no distinction between background negative controls and placenta samples | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3BCUKEU3X | ||||||
| Subjects: | 40 | ||||||
| Study PI, contact: |
|
||||||
| Publications: | None | ||||||
| Resources: |
|
||||||
| Assays: |
|
||||||
| Clinical Assessments: |
|
||||||
| SDY1409: MaHPIC: Host M. mulatta infected with homologous and heterologous strains of P. cynomolgi | |||||||||
| Status: | New | ||||||||
| Description: | Experiment 23 (Initial challenge with P. cynomolgi B strain) - Malaria-naive male rhesus macaques (Macaca mulatta), approximately four years of age, were inoculated intravenously with salivary gland sporozoites produced and isolated at the Centers for Disease Control and Prevention from multiple Anopheles species (An. dirus, An. gambiae, and An. stephensi) and then profiled for clinical, hematological, parasitological, immunological, functional genomic, lipidomic, proteomic, and metabolomic measurements. The experiment was designed for about 100 days, with pre- and post-100 day periods to prepare subjects and administer curative treatments respectively. During the 100-day period subjects experienced periods of patent and sub-patent infection. The anti-malarial drug artemether was subcuratively administered to subjects after the initial peak of infection, if subjects were not able to self-resolve. Blood-stage curative artemether was administered to all subjects following peak infection, and following a period of relapse infection. All peaks were clinically determined for each subject. The anti-malarial drugs primaquine and chloroquine were administered to all subjects at the end of the study for curative treatment of the liver and blood-stage infections, respectively. Capillary blood samples were collected daily for the measurement of CBCs, reticulocytes, and parasitemias. Capillary blood samples were collected every other day to obtain plasma for metabolomic analysis. Venous blood and bone marrow samples were collected at seven time points for functional genomic, proteomic, lipidomic, and immunological analyses. Within the MaHPIC, this project is known as 'Experiment 23'. This is an iteration of Experiment 04 with the same parasite-host combination and sampling and treatment adjustments made, and this is the first in a series of experiments that includes subsequent homologous (Experiment 24, P. cynomolgi B strain) and heterologous (Experiment 25, P. cynomolgi strain ceylonensis) challenges of individuals from the Experiment 23 cohort. One subject was not included in subsequent experiments due to persistent behavioral issues that prevented sample collection. Experiment 24 (Homologous challenge with P. cynomolgi B strain) - Male rhesus macaques (Macaca mulatta), cleared of previous infection with P. cynomolgi B strain via treatment with the anti-malarial drugs artemether, chloroquine, and primaquine, approximately five years of age, were inoculated intravenously with salivary gland sporozoites produced and isolated at the Centers for Disease Control and Prevention from multiple Anopheles species (An. dirus, An. gambiae, and An. stephensi) and then profiled for clinical, hematological, parasitological, immunological, functional genomic, lipidomic, and metabolomic measurements. The experiment included, 1 pre-inoculation day, 35 experiment days, and 10 post-experiment days. The anti-malarial drugs primaquine and chloroquine were administered to all subjects at the end of the study for curative treatment of the liver and blood-stage infections, respectively. Capillary blood samples were collected daily for the measurement of CBCs, reticulocytes, and parasitemias. Capillary blood samples were collected every other day to obtain plasma for metabolomic analysis. Venous blood samples were collected at three time points for functional genomic, lipidomic, and immunological analyses. Within the MaHPIC, this project is known as 'Experiment 24'. This is the second in a series of experiments that includes infection of malaria-naive subjects (Experiment 23, P. cynomolgi B strain) and heterologous challenge (Experiment 25, P. cynomolgi strain ceylonensis) for the individuals from the same cohort. Experiment 25 (Heterologous challenge with P. cynomolgi strain ceylonensis) - Male rhesus macaques (Macaca mulatta), cleared of previous infection with P. cynomolgi B strain via treatment with the anti-malarial drugs artemether, chloroquine, and primaquine, approximately five years of age, were inoculated intravenously with salivary gland sporozoites produced and isolated at the Centers for Disease Control and Prevention from multiple Anopheles species (An. dirus, An. gambiae, and An. stephensi) and then profiled for clinical, hematological, parasitological, immunological, functional genomic, lipidomic, proteomic, and metabolomic measurements. The experiment included, 8 pre-inoculation days, 49 experiment days, and 4 post-experiment days. The anti-malarial drug artemether was subcuratively administered to subjects at the initial peak of infection, if subjects were not able to self-resolve their parasitemias. Peak infection was determined clinically for each subject. The anti-malarial drugs primaquine and chloroquine were administered to all subjects at the end of the study for curative treatment of the liver and blood-stage infections, respectively. Capillary blood samples were collected daily for the measurement of CBCs, reticulocytes, and parasitemias. Capillary blood samples were collected every other day to obtain plasma for metabolomic analysis. Venous blood samples were collected at five time points for functional genomic, lipidomic, proteomic, and immunological analyses. Within the MaHPIC, this project is known as 'Experiment 25'. This is the third and final of a series of experiments that includes infection of malaria-naive subjects (Experiment 23, P. cynomolgi B strain) and homologous challenge (Experiment 24, P. cynomolgi B strain) of individuals from the same cohort. These datasets were produced by Mary Galinski, Rabindra Tirouvanziam, and Tracey Lamb at Emory University. To access other publicly available results from 'E23', 'E24', 'E25', and other MaHPIC Experiments, including clinical results (specifics on drugs administered, diet, and veterinary interventions), and other omics, visit http://plasmodb.org/plasmo/mahpic.jsp . This page will be updated as datasets are released to the public. The experimental design and protocols for this study were approved by the Emory University Institutional Animal Care and Use Committee (IACUC). |
||||||||
| Program/Contract: |
|
||||||||
| DOI: | 10.21430/M3TSYO4T3L | ||||||||
| Subjects: | 6 | ||||||||
| Study PI, contact: |
|
||||||||
| Publications: | None | ||||||||
| Resources: |
|
||||||||
| Assays: |
|
||||||||
| Clinical Assessments: | None | ||||||||
| SDY1411: MaHPIC: Host M. mulatta infected with P. coatneyi | |||||||
| Status: | New | ||||||
| Description: | Malaria-naive male rhesus macaques (Macaca mulatta), approximately four years of age, were inoculated intravenously with salivary gland sporozoites produced and isolated at the Centers for Disease Control and Prevention from multiple Anopheles species (An. dirus, An. gambiae, and An. stephensi) and then profiled for clinical, hematological, parasitological, immunological, functional genomic, lipidomic, proteomic, and metabolomic measurements. The experiment was designed for 100 days, and pre- and post-100 day periods to prepare subjects and administer curative treatments respectively. The anti-malarial drug artemether was subcuratively administered to all subjects at the initial peak of infection, one out of the five macaques received four additional subcurative treatments for subsequent recrudescence peaks. The experimental infection in one subject was ineffective but the macaque was followed-up for the same period of 100 days. The different clinical phases of the infection were clinically determined for each subject. Blood-stage curative doses of artemether were administered to all subjects at the end of the study. Capillary blood samples were collected daily for the measurement of CBCs, reticulocytes, and parasitemias. Capillary blood samples were collected every other day to obtain plasma for metabolomic analysis. Venous blood and bone marrow samples were collected at seven time points for functional genomic, proteomic, lipidomic, and immunological analyses. Within the MaHPIC, this project is known as "Experiment 03". This dataset was produced by Mary Galinski, Rabindra Tirouvanziam, and Tracey Lamb at Emory University. To access other publicly available results from 'E03' and other MaHPIC Experiments, including clinical results (specifics on drugs administered, diet, and veterinary interventions), and other omics, visit http://plasmodb.org/plasmo/mahpic.jsp . This page will be updated as datasets are released to the public. The experimental design and protocols for this study were approved by the Emory University Institutional Animal Care and Use Committee (IACUC). | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3J2FJIVPW | ||||||
| Subjects: | 5 | ||||||
| Study PI, contact: |
|
||||||
| Publications: | None | ||||||
| Resources: |
|
||||||
| Assays: |
|
||||||
| Clinical Assessments: | None | ||||||
| SDY1418: Multiomics modeling of the immunome, transcriptome, microbiome, proteome and metabolome adaptations during human pregnancy | |||||||||||||
| Status: | New | ||||||||||||
| Description: | Biological mechanisms produce immunologic, metabolomic, proteomic, genomic and microbiomic adaptations during the course of pregnancy. | ||||||||||||
| Program/Contract: |
|
||||||||||||
| DOI: | 10.21430/M302L1ULGW | ||||||||||||
| Subjects: | 31 | ||||||||||||
| Study PI, contact: |
|
||||||||||||
| Publications: |
|
||||||||||||
| Resources: |
|
||||||||||||
| Assays: | None | ||||||||||||
| Clinical Assessments: | None | ||||||||||||
| SDY1424: MaHPIC: Host Aotus nancymaae infected with P. vivax Brazil VII | |||||||
| Status: | New | ||||||
| Description: | Malaria-naive Aotus nancymaae were inoculated intravenously with salivary gland sporozoites produced and isolated at the Centers for Disease Control and Prevention from multiple Anopheles species (An. gambiae, An. stephensi, and An. freeborni) then profiled for clinical, hematological, parasitological, immunological, functional genomic, and metabolomic measurements. The experiment was performed for 121 days. The first inoculation attempt was virtually unsuccessful as only one of seven animals developed blood-stage infection. This animal was treated for the blood-stage infection. All animals were re-challenged approximately one month later. Upon re-challenge all animals developed blood-stage infections with similar parasitological kinetics. After infections became chronic, the anti-malarial drug artemether was administered to curatively treat blood-stage infections. No sub-curative treatments were administered during this study because none of the animals developed severe disease. At the end of the study, the anti-malarial drugs primaquine and chloroquine were administered to all animals for curative treatment of the liver and blood-stage infections, respectively. Venous blood samples were collected only on clinically determined 'timepoint' days for the measurement of CBCs, reticulocytes, parasitemias, and downstream omics and immunological analyses. Small sample volumes were collected daily or every other day for the measurement of parasitemia. Within the MaHPIC, this project is known as 'Experiment 15'. This dataset was produced by John Barnwell at the CDC. To access other publicly available results from E15 and other MaHPIC Experiments, including clinical results (specifics on drugs administered), and other omics, visit http://plasmodb.org/plasmo/mahpic.jsp. This page will be updated as datasets are released to the public. The experimental design and protocols for this study were approved by the Emory University Institutional Animal Care and Use Committee (IACUC). | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M32LN9GIBL | ||||||
| Subjects: | 7 | ||||||
| Study PI, contact: |
|
||||||
| Publications: | None | ||||||
| Resources: |
|
||||||
| Assays: |
|
||||||
| Clinical Assessments: | None | ||||||
| SDY1425: Optimization of Belatacept Usage As A Means of Avoiding CNI and steroids in Renal Transplantation | |||||||
| Status: | New | ||||||
| Description: | Dialysis or kidney transplant are the two ways to treat kidney failure. Transplant recipients have to take anti-rejection medications to prevent their immune system (the body's natural defense system against illness) from rejecting their new kidney. Most patients who undergo a kidney transplant must take these anti-rejection medications for the rest of their lives. Taking standard anti-rejection medications for a long time can cause serious side effects, including kidney damage. There would be a benefit to finding new anti-rejection medications that work just as well, but don't damage the kidney. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3W0NBNCXA | ||||||
| Subjects: | 19 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: | None | ||||||
| Clinical Assessments: | None | ||||||
| SDY1426: Prior dengue virus infection and risk of Zika: a pediatric cohort in Nicaragua | |||||||
| Status: | New | ||||||
| Description: | We describe the introduction of ZIKV into the Pediatric Dengue Cohort Study, a long-standing pediatric dengue cohort established in 2004 in Managua, Nicaragua, in which the DENV immune history of the participants is well-characterized. The incidence of symptomatic and inapparent ZIKV infections in 2016 was estimated, together with associated demographic risk factors. The effect of previous DENV infection on ZIKV infection and disease was also analyzed. Data are available upon request (eharris@berkeley.edu), as is required by the IRB-approved protocol for the Pediatric Dengue Cohort Study. The materials and data used in this study are covered by standard material transfer agreements. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3IBGBX9JO | ||||||
| Subjects: | 0 | ||||||
| Study PI, contact: |
|
||||||
| Publications: | None | ||||||
| Resources: |
|
||||||
| Assays: | None | ||||||
| Clinical Assessments: | None | ||||||
| SDY89: Systems Biology Analysis of the response to Licensed Hepatitis B Vaccine (Engerix-B) (see companion study SDY690) | |||||||||
| Status: | Updated | ||||||||
| Description: | This project will contribute to the overall vision and goals of this U19 by analyzing the role of adjuvants in the humoral response to hep B vaccination in healthy individuals. | ||||||||
| Program/Contract: |
|
||||||||
| DOI: | 10.21430/M3AYWX8NOT | ||||||||
| Subjects: | 50 | ||||||||
| Study PI, contact: |
|
||||||||
| Publications: |
|
||||||||
| Resources: |
|
||||||||
| Assays: |
|
||||||||
| Clinical Assessments: | None | ||||||||
| SDY224: Immune Responses to Seasonal TIV 2010-2011 Influenza Vaccination in Humans (see companion study SDY396,SDY564) | |||||||||||||||
| Status: | Updated | ||||||||||||||
| Description: | High-frequency sampling combined with systems biology analysis of human peripheral blood cells following influenza vaccination was used to investigate T cell and B cell responses. Functional principal component analysis was used to examine time varying B cell vaccine response highlighting a single subject-specific mathematical pattern explaining ninety percent of the transcriptome variation. In addtition, daily sampling and monitoring of the proliferation marker Ki-67, revealed influenza-specific CD4 T cells do respond to vaccination. | ||||||||||||||
| Program/Contract: |
|
||||||||||||||
| DOI: | 10.21430/M37KMO7JLW | ||||||||||||||
| Subjects: | 14 | ||||||||||||||
| Study PI, contact: |
|
||||||||||||||
| Publications: |
|
||||||||||||||
| Resources: |
|
||||||||||||||
| Assays: |
|
||||||||||||||
| Clinical Assessments: | None | ||||||||||||||
| SDY299: Systems Biology Analysis of the response to Licensed Hepatitis B Vaccine (HEPLISAV) in Whole Blood (see companion studies SDY816 and SDY690) | |||||||
| Status: | Updated | ||||||
| Description: | This project will contribute to the overall vision and goals of this U19 by analyzing the role of adjuvants in the humoral response to hep B vaccination in healthy individuals. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M34QI37OT9 | ||||||
| Subjects: | 25 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: |
|
||||||
| Clinical Assessments: | None | ||||||
| SDY520: Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400) | |||||||
| Status: | Updated | ||||||
| Description: | Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013 | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3KVVHM735 | ||||||
| Subjects: | 61 | ||||||
| Study PI, contact: |
|
||||||
| Publications: | None | ||||||
| Resources: |
|
||||||
| Assays: |
|
||||||
| Clinical Assessments: | None | ||||||
| SDY820: Human Immune Signature of Mycobacterium Tuberculosis infection. (See SDY1324 for sorted cell gene expression data) | |||||||||
| Status: | Updated | ||||||||
| Description: | The human immune signature of latent Mycobacterium tuberculosis infected patients as well as BCG vaccinated and BCG non-vaccinated individuals was studied by flow cytometry | ||||||||
| Program/Contract: |
|
||||||||
| DOI: | 10.21430/M3D02NOSVH | ||||||||
| Subjects: | 60 | ||||||||
| Study PI, contact: |
|
||||||||
| Publications: |
|
||||||||
| Resources: |
|
||||||||
| Assays: |
|
||||||||
| Clinical Assessments: | None | ||||||||
| SDY998: AMP Rheumatoid Arthritis Arthroplasty Phase 1 | ||||||||||||||||||||||||||||
| Status: | Updated | |||||||||||||||||||||||||||
| Description: | The primary goal for RA arthroplasty P1 studies are: To establish if molecular signatures and pathways identified using core AMP technologies differ between OA and RA in 20 RA surgical samples and 10 OA arthroplasty samples. | |||||||||||||||||||||||||||
| Program/Contract: |
|
|||||||||||||||||||||||||||
| DOI: | 10.21430/M3KXJHSP4T | |||||||||||||||||||||||||||
| Subjects: | 40 | |||||||||||||||||||||||||||
| Study PI, contact: |
|
|||||||||||||||||||||||||||
| Publications: | None | |||||||||||||||||||||||||||
| Resources: |
|
|||||||||||||||||||||||||||
| Assays: |
|
|||||||||||||||||||||||||||
| Clinical Assessments: |
|
|||||||||||||||||||||||||||
| SDY999: AMP Rheumatoid Arthritis Synovial Phase 1 | |||||||||||||||||||||||||
| Status: | Updated | ||||||||||||||||||||||||
| Description: | The primary goal for RA synovial P1 studies are: To establish feasibility of obtaining ultrasound-guided synovial biopsies in the United States (U.S.) by comparing to frozen synovial biopsies obtained in the United Kingdom (U.K.) | ||||||||||||||||||||||||
| Program/Contract: |
|
||||||||||||||||||||||||
| DOI: | 10.21430/M3XRJHRPBC | ||||||||||||||||||||||||
| Subjects: | 22 | ||||||||||||||||||||||||
| Study PI, contact: |
|
||||||||||||||||||||||||
| Publications: | None | ||||||||||||||||||||||||
| Resources: |
|
||||||||||||||||||||||||
| Assays: |
|
||||||||||||||||||||||||
| Clinical Assessments: |
|
||||||||||||||||||||||||
| SDY1025: APIC | ||||||||||||
| Status: | Updated | |||||||||||
| Description: | This study looks to define the phenotypic characteristics of Difficult-to-Treat asthma, among 650 children between the ages of 6 to 17 years, receiving one year of guidelines-based therapy for asthma and rhinitis/rhinosinusitis. | |||||||||||
| Program/Contract: |
|
|||||||||||
| DOI: | 10.21430/M39SEUM79K | |||||||||||
| Subjects: | 717 | |||||||||||
| Study PI, contact: |
|
|||||||||||
| Publications: |
|
|||||||||||
| Resources: |
|
|||||||||||
| Assays: | None | |||||||||||
| Clinical Assessments: |
|
|||||||||||
| SDY1026: BioCSI 2 (Biomarkers of Cockroach Sublingual Immunotherapy 2) | |||||||
| Status: | Updated | ||||||
| Description: | This study looks to compare two doses of glycerinated German cockroach allergenic extract versus placebo administered via the sublingual route in 99 children ages 5 to 17 years with perennial allergic rhinitis, asthma, or both. It is designed to study biomarkers of the immune response to allergen immunotherapy as well as the safety of this therapy. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3LVUFRQOA | ||||||
| Subjects: | 99 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: | None | ||||||
| Clinical Assessments: | None | ||||||
| SDY1027: Epigenetics | |||||||||||||
| Status: | Updated | ||||||||||||
| Description: | The study is designed to determine the relation between methylation of CpG motifs and asthma in children residing in the inner city. | ||||||||||||
| Program/Contract: |
|
||||||||||||
| DOI: | 10.21430/M3SXDBHQTS | ||||||||||||
| Subjects: | 200 | ||||||||||||
| Study PI, contact: |
|
||||||||||||
| Publications: |
|
||||||||||||
| Resources: |
|
||||||||||||
| Assays: |
|
||||||||||||
| Clinical Assessments: | None | ||||||||||||
| SDY1028: Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations (PROSE) | ||||||||||
| Status: | Updated | |||||||||
| Description: | A three-armed prospective randomized double-blind placebo-controlled trial investigating the efficacy of standard care plus 4-5 months of treatment with (a) a boost of inhaled corticosteroid therapy Flovent Diskus (fluticasone) versus (b) Xolair(omalizumab) or (c) placebo Xolair (omalizumab) and placebo Flovent Diskus (fluticasone) in reducing the exacerbations during the fall season. | |||||||||
| Program/Contract: |
|
|||||||||
| DOI: | 10.21430/M3HZZOS3Y5 | |||||||||
| Subjects: | 513 | |||||||||
| Study PI, contact: |
|
|||||||||
| Publications: |
|
|||||||||
| Resources: |
|
|||||||||
| Assays: | None | |||||||||
| Clinical Assessments: |
|
|||||||||
| SDY1029: SCITCO (Subcutaneous Immunotherapy for Cockroach) | |||||||
| Status: | Updated | ||||||
| Description: | This is an open label single site trial of German cockroach allergenic extract administered by subcutaneous injection in 10 adults ages 18 to 55 years with perennial allergic rhinitis, asthma, or both. It is designed to study biomarkers of the immune response to allergen immunotherapy as well as the safety of this therapy. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3XJ80W9FK | ||||||
| Subjects: | 11 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: | None | ||||||
| Clinical Assessments: | None | ||||||
| SDY1176: Extensive homeostatic T cell phenotypic variation within the Collaborative Cross | |||||||
| Status: | Updated | ||||||
| Description: | The Collaborative Cross (CC) is a panel of reproducible recombinant inbred mouse strains with high levels of standing genetic variation, thereby affording unprecedented opportunity to perform experiments in a small animal model containing controlled genetic diversity while allowing for genetic replicates. Here, we advance the utility of this unique mouse resource for immunology research, as it allows for both examination and genetic dissection of mechanisms behind adaptive immune states in mice with distinct and defined genetic makeups. This approach is founded on quantitative trait locus mapping: identifying genetically variant genome regions associated with phenotypic variance in traits-of-interest. Furthermore, the CC can be utilized for mouse model development; distinct strains have unique immunophenotypes and immune properties, making them suitable for research on particular diseases and infections. Here, we describe variation in cellular immune phenotypes across F1 crosses of CC strains, and reveal novel quantitative trait loci responsible for several immune phenotypes. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3RKBKOYKS | ||||||
| Subjects: | 476 | ||||||
| Study PI, contact: |
|
||||||
| Publications: | None | ||||||
| Resources: |
|
||||||
| Assays: |
|
||||||
| Clinical Assessments: | None | ||||||
| SDY1289: YFV integrated mulitlineage and polyfunctional responses | |||||||
| Status: | Updated | ||||||
| Description: | Correlates of immune-mediated protection to most viral and cancer vaccines are still unknown. This impedes the development of novel vaccines to incurable diseases such as HIV and cancer. In this study, we have used functional genomics and polychromatic flow cytometry to define the signature of the immune response to the yellow fever (YF) vaccine 17D (YF17D) in a cohort of 40 volunteers followed for up to 1 yr after vaccination. We show that immunization with YF17D leads to an integrated immune response that includes several effector arms of innate immunity, including complement, the inflammasome, and interferons, as well as adaptive immunity as shown by an early T cell response followed by a brisk and variable B cell response. Development of these responses is preceded, as demonstrated in three independent vaccination trials and in a novel in vitro system of primary immune responses (modular immune in vitro construct [MIMIC] system), by the coordinated up-regulation of transcripts for specific transcription factors, including STAT1, IRF7, and ETS2, which are upstream of the different effector arms of the immune response. These results clearly show that the immune response to a strong vaccine is preceded by coordinated induction of master transcription factors that lead to the development of a broad, polyfunctional, and persistent immune response that integrates all effector cells of the immune system. peripheral blood samples from human newborns | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M37CO9E6FQ | ||||||
| Subjects: | 30 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: |
|
||||||
| Clinical Assessments: | None | ||||||
| SDY1325: B-cell responses to meningococcal vaccine. | |||||||
| Status: | Updated | ||||||
| Description: | Background: Neisseria meningitidis is a globally important cause of meningitis and septicaemia. Twelve capsular groups of meningococci are known, and quadrivalent vaccines against four of these (A, C, W and Y) are available as plain-polysaccharide and protein-polysaccharide conjugate vaccines. Here we apply contemporary methods to describe B-cell responses to meningococcal polysaccharide and conjugate vaccines. Methods: Twenty adults were randomly assigned to receive either a meningococcal plain-polysaccharide or conjugate vaccine; one month later all received the conjugate vaccine. Blood samples were taken pre-vaccination and 7, 21 and 28 days after vaccination; B-cell responses were assessed by ELISpot, serum bactericidal assay, flow cytometry and gene expression microarray. Results: Seven days after an initial dose of either vaccine, a gene expression signature characteristic of plasmablasts was detectable. The frequency of newly generated plasma cells (CXCR3+HLA-DR+) and the expression of transcripts derived from IGKC and IGHG2 correlated with immunogenicity. Notably, using an independent dataset, the expression of glucosamine (N-acetyl)-6-sulfatase was found to reproducibly correlate with the magnitude of immune response. Transcriptomic and flow cytometric data revealed depletion of switched memory B cells following plain-polysaccharide vaccine. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3Q1ZBWOG2 | ||||||
| Subjects: | 20 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: |
|
||||||
| Clinical Assessments: | None | ||||||